Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML

Harrison Silva, Grace Martin, Filippo Birocchi, Marc Wehrli, Michael C Kann, Valentina M Supper, Aiyana Parker, Charlotte E Graham, Alexandra Grace Bratt, Amanda A Bouffard, Hannah Donner, Giulia Escobar, Hana N Takei, Alexander Armstrong, Sadie Goncalves, Trisha R Berger, Bryan D. Choi, Marcela V Maus, Mark B Leick

Blood blood.2023023210.

https://doi.org/10.1182/blood.2023023210

Published: 2024

Includes: Supplemental data

Journal Articles

Novel CD2-Targeting Trispecific Immune Effector Cell Engager (TRIEC) Coupled with CD19 CAR-T Overcomes Resistant B-Cell Lymphoma

Elijah P Darnell, Hana N Takei, Mark B Leick, Filippo Birocchi, Amanda A Bouffard, Trisha R Berger, Marcela V Maus

Blood (2024) 144 (Supplement 1): 2025.

https://doi.org/10.1182/blood-2024-194688

Published: 2024

Journal Articles

Biological Correlatives of Efficacy and Toxicity of BCMA Targeting CAR T Cell Therapy in a Real-World Setting

Blood (2024) 144 (Supplement 1): 7126.

https://doi.org/10.1182/blood-2024-194895

Published: 2024

Journal Articles

Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37 + lymphoid malignancies

Blood (2024) 144 (11): 1153–1167.

https://doi.org/10.1182/blood.2024024104

Published: 2024

Includes: Supplemental data

Journal Articles

Tumor burden in ZUMA-7: less is more

Eli P. Darnell, Marcela V. Maus

Blood (2024) 143 (24): 2441–2442.

https://doi.org/10.1182/blood.2024024592

Published: 2024

Journal Articles

Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System

Magdi Elsallab, Moataz Ellithi, Matthew A. Lunning, Christopher D’Angelo, Jihyun Ma, Miguel-Angel Perales, Matthew Frigault, Marcela V. Maus

Blood (2024) 143 (20): 2099–2105.

https://doi.org/10.1182/blood.2024024166

Published: 2024

Includes: Supplemental data

Journal Articles

A Lenalidomide-Inducible Suicide Switch for Gene- and Cell-Based Therapy

William Lin, Ditsa Sarkar, Joanna Y Kim, Nelson H Knudsen, Isabel C Lane, Andi Cheng, Gabriele Kembaun, Tamina Kienka, Jeannie Carreiro, Amanda A Bouffard, Marcela V Maus, Robert T Manguso, Max Jan

Blood (2023) 142 (Supplement 1): 4825.

https://doi.org/10.1182/blood-2023-189628

Published: 2023

Journal Articles

Affinity Matured CD72 CAR-T Improves Efficacy Versus Low Antigen Density B-Cell Non-Hodgkin Lymphoma Models

Adila Izgutdina, William C Temple, Matthew Andrew Nix, Huimin Geng, Emilio Ramos, Akul Naik, Rebecca Larson, Fernando Salangsang, Paul Phojanakong, Juan Antonio Camara Serrano, Ons Zakraoui, Isa Tariq, Marcela V Maus, Veronica Steri, Arun P Wiita

Blood (2023) 142 (Supplement 1): 2068.

https://doi.org/10.1182/blood-2023-182873

Published: 2023

Journal Articles

Chemotherapy-induced reversal of ciltacabtagene autoleucel–associated movement and neurocognitive toxicity

Charlotte E. Graham, Won-Ho Lee, Hadley R. Wiggin, Valentina M. Supper, Mark B. Leick, Filippo Birocchi, Andrew J. Yee, Angelina Petrichenko, John Everett, Frederic D. Bushman, Hossein Sadrzadeh, Otto Rapalino, Daniel Chiu, Isabel Arrillaga-Romany, Marcela V. Maus, Matthew J. Frigault, Kathleen M. E. Gallagher

Blood (2023) 142 (14): 1248–1252.

https://doi.org/10.1182/blood.2023021429

Published: 2023

Includes: Supplemental data

Journal Articles

Signatures of dysfunctional CAR T cells

Marcela V. Maus

Blood (2023) 141 (26): 3127–3129.

https://doi.org/10.1182/blood.2023020935

Published: 2023

Journal Articles

Immunologic Responses to Sars-Cov-2 Vaccination in Myeloproliferative Neoplasm Patients: Durability, Booster Responses, and Associations with Infections

Joan How, Kathleen M.E. Gallagher, Yiwen Liu, Katelin Katsis, Eva Elder, Donna S. Neuberg, Patrick M. Reeves, Marcela V. Maus, Gabriela S. Hobbs

Blood (2022) 140 (Supplement 1): 6852–6853.

https://doi.org/10.1182/blood-2022-157628

Published: 2022

Journal Articles

Combinatorial Effects of BH3 Mimetics and CAR T Cells Targeting T-Cell Lymphomas

Tayla B. Heavican-Foral, Felix Korell, Irene Scarfò, Harrison Silva, Allen Basanthakumar, Foster Powers, David M. Weinstock, Marcela V. Maus, Birgit Knoechel

Blood (2022) 140 (Supplement 1): 499–500.

https://doi.org/10.1182/blood-2022-159647

Published: 2022

Journal Articles

Bispecific CD33/CD123 Targeted Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia

Justin C. Boucher, Bishwas Shrestha, Paresh Vishwasrao, Mark B. Leick, Nhan Tu, Tayyebb Ghafoor, Kayla M. Reid, Kristen Spitler, Bin Yu, Marcela V. Maus, Marco L. Davila

Blood (2022) 140 (Supplement 1): 10275–10276.

https://doi.org/10.1182/blood-2022-163299

Published: 2022

Journal Articles

Patients with Deleterious Germline Variants in STXBP2 Develop Toxicity after CAR-T Cell Therapy with Axicabtagene Ciloleucel

Blood (2022) 140 (Supplement 1): 646–647.

https://doi.org/10.1182/blood-2022-166322

Published: 2022

Journal Articles

Safety of genetically modified T cells

Marcela V. Maus

Blood (2022) 140 (1): 1–2.

https://doi.org/10.1182/blood.2022016334

Published: 2022

Journal Articles

Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial

Blood (2022) 139 (15): 2306–2315.

https://doi.org/10.1182/blood.2021014738

Published: 2022

Includes: Supplemental data

Journal Articles

Blocking IFNγ in CAR-T Reduces Checkpoint Inhibitors and Cell-Mediated Toxicity without Compromising Therapeutic Efficacy in CD19 + malignancies

Stefanie R. Bailey, Sonika Vatsa, Rebecca Larson, Amanda A Bouffard, Irene Scarfò, Kathleen M.E. Gallagher, Matthew J. Frigault, Marcela V. Maus

Blood (2021) 138 (Supplement 1): 1723.

https://doi.org/10.1182/blood-2021-146042

Published: 2021

Journal Articles

Effects of Prior Exposure to Tec Kinase(BTK/ITK) Inhibitors on Kte-X19 Products

Irene Scarfò, Kathleen M.E. Gallagher, Mark B. Leick, Michael C. Kann, Justin Budka, Bharat Sowrirajan, Kim Nguyen, Rhine R. Shen, Adrian Bot, Marcela V. Maus

Blood (2021) 138 (Supplement 1): 3849.

https://doi.org/10.1182/blood-2021-146941

Published: 2021

Journal Articles

Phase 1 Study of CD37-Directed CAR T Cells in Patients with Relapsed or Refractory CD37+ Hematologic Malignancies

Matthew J. Frigault, Yi-Bin Chen, Kathleen M.E. Gallagher, Nora K. Horick, Areej El-Jawahri, Irene Scarfò, Marc Wehrli, Lu Huang, Keagan Casey, Daniella Cook, Thomas Spitzer, Steven McAfee, Frederic I. Preffer, Myriam Armant, Kit L. Shaw, Heather Daley, Sarah Nikiforow, Jerome Ritz, Marcela V. Maus

Blood (2021) 138 (Supplement 1): 653.

https://doi.org/10.1182/blood-2021-146236

Published: 2021

Journal Articles

Rational Chemical and Genetic Modifications Enhance Avidity and Function of CD70-Directed CAR-T-Cells for Myeloid Leukemia

Mark B. Leick, Harrison Silva, Irene Scarfò, Rebecca Larson, Bryan D. Choi, Amanda A Bouffard, Kathleen M.E. Gallagher, Andrea Schmidts, Stefanie R. Bailey, Michael C. Kann, Max Jan, Marc Wehrli, Korneel Grauwet, Matthew J. Frigault, Marcela V. Maus

Blood (2021) 138 (Supplement 1): 405.

https://doi.org/10.1182/blood-2021-150596

Published: 2021

NARROW

CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML

Novel CD2-Targeting Trispecific Immune Effector Cell Engager (TRIEC) Coupled with CD19 CAR-T Overcomes Resistant B-Cell Lymphoma

Biological Correlatives of Efficacy and Toxicity of BCMA Targeting CAR T Cell Therapy in a Real-World Setting

Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37 + lymphoid malignancies

Tumor burden in ZUMA-7: less is more

Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System

A Lenalidomide-Inducible Suicide Switch for Gene- and Cell-Based Therapy

Affinity Matured CD72 CAR-T Improves Efficacy Versus Low Antigen Density B-Cell Non-Hodgkin Lymphoma Models

Chemotherapy-induced reversal of ciltacabtagene autoleucel–associated movement and neurocognitive toxicity

Signatures of dysfunctional CAR T cells

Immunologic Responses to Sars-Cov-2 Vaccination in Myeloproliferative Neoplasm Patients: Durability, Booster Responses, and Associations with Infections

Combinatorial Effects of BH3 Mimetics and CAR T Cells Targeting T-Cell Lymphomas

Bispecific CD33/CD123 Targeted Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia

Patients with Deleterious Germline Variants in STXBP2 Develop Toxicity after CAR-T Cell Therapy with Axicabtagene Ciloleucel

Safety of genetically modified T cells

Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial

Blocking IFNγ in CAR-T Reduces Checkpoint Inhibitors and Cell-Mediated Toxicity without Compromising Therapeutic Efficacy in CD19 + malignancies

Effects of Prior Exposure to Tec Kinase(BTK/ITK) Inhibitors on Kte-X19 Products

Phase 1 Study of CD37-Directed CAR T Cells in Patients with Relapsed or Refractory CD37+ Hematologic Malignancies

Rational Chemical and Genetic Modifications Enhance Avidity and Function of CD70-Directed CAR-T-Cells for Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only